Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Verapamil · Verapamil Hydrochloride

Small molecule · Antagonist of L-type calcium channel · developed by Pfizer

Approved FDA, Sep 1984

1 Registered trials

What is Verapamil?

Verapamil is a phenylalkylamine calcium channel antagonist that inhibits transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing coronary and systemic artery dilatation and decreasing myocardial contractility.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Verapamil Hydrochloride
Drug type: Small molecule
Targets: L-type calcium channel, P-glycoprotein (ABCB1) (secondary target)
Mechanism: Antagonist of L-type calcium channel
Pathways: calcium signaling, vascular smooth muscle contraction
Therapy area: Cardiovascular
Developer: Pfizer
In trials of: EWTX
FDA status: Approved as Verapamil Hydrochloride (September 10, 1984), NDA018817 · FDA label
UNII: QR5PYD126V

✅ FDA-approved uses

Hypertension

From the indications section of the FDA label (version of Mar 25, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06916897	Phase 1	Healthy Subjects	Completed	EWTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Subjects

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z